A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.
Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback